XE7C Stock Overview
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.73 |
| 52 Week High | US$5.59 |
| 52 Week Low | US$0.87 |
| Beta | 1.97 |
| 1 Month Change | -24.37% |
| 3 Month Change | 162.69% |
| 1 Year Change | 142.51% |
| 3 Year Change | -54.29% |
| 5 Year Change | 18.59% |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| XE7C | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.2% | 0.8% | 1.2% |
| 1Y | 142.5% | -24.4% | 2.0% |
Return vs Industry: XE7C exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: XE7C exceeded the German Market which returned 2% over the past year.
Price Volatility
| XE7C volatility | |
|---|---|
| XE7C Average Weekly Movement | 22.1% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: XE7C's share price has been volatile over the past 3 months.
Volatility Over Time: XE7C's weekly volatility has increased from 14% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Mark Erlander | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers.
Cardiff Oncology, Inc. Fundamentals Summary
| XE7C fundamental statistics | |
|---|---|
| Market cap | €169.72m |
| Earnings (TTM) | -€38.67m |
| Revenue (TTM) | €455.16k |
408.6x
P/S Ratio-4.8x
P/E RatioIs XE7C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XE7C income statement (TTM) | |
|---|---|
| Revenue | US$488.00k |
| Cost of Revenue | US$32.86m |
| Gross Profit | -US$32.37m |
| Other Expenses | US$9.10m |
| Earnings | -US$41.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.93 |
| Gross Margin | -6,632.99% |
| Net Profit Margin | -8,496.93% |
| Debt/Equity Ratio | 0% |
How did XE7C perform over the long term?
See historical performance and comparison